LKFT · Lakefront Biotherapeutics NV · Documents
$32.28
-0.05 (-0.15%)
At close · Oct 30
Return incl. dividend (before tax)
Q1 2026 earnings call transcript
Market Cap
$2.13B
Shares
65.90M
Volume · Oct 30
164.06K
Avg daily vol (3M)
283.93K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Lakefront Biotherapeutics NV repurchased 107,804 shares between October 12, 2026, and October 16, 2026, paying 2,854,365.69 euros, fully completing its repurchase program announced on June 9, 2026, and held 1,985,157 own ordinary shares at market close on October 16, 2026. | 2026-10-20 | — | |
| 6-K | Lakefront Biotherapeutics NV sold its early-stage cell therapy pipeline to Armed Cell Therapeutics BV for €8 million upfront, potential milestone payments of up to $230 million and a low-single-digit royalty; the wind-down of cell therapy activities is substantially complete. | 2026-10-15 | 2026-10-14 | |
| 6-K | Lakefront Biotherapeutics NV repurchased 126,322 shares between October 05, 2026 and October 09, 2026 for €3,317,407.94 at an average price of €26.26; it held 1,877,353 own shares as of market close on October 9, 2026. | 2026-10-13 | — | |
| 6-K | Lakefront Biotherapeutics NV said Bank of America Corporation crossed below 10% of its voting rights on October 2, 2026, leaving 8.54% ownership after disposing of voting rights and equivalent financial instruments. | 2026-10-09 | 2026-10-08 | |
| 6-K | Lakefront Biotherapeutics NV repurchased 117,437 shares between September 28, 2026, and October 02, 2026 under its June 9, 2026 repurchase program; it held 1,751,031 own ordinary shares as of market close on October 02, 2026. | 2026-10-06 | — | |
| 6-K | Lakefront Biotherapeutics NV repurchased 106,060 shares between September 21, 2026, and September 25, 2026, totaling 2,795,740.67 at an average price paid of 26.36; it held 1,633,594 own ordinary shares at the September 25, 2026 market close. | 2026-09-29 | — | |
| 6-K | Lakefront Biotherapeutics NV repurchased 108,679 shares between September 14, 2026 and September 18, 2026 for €2,608,832.08 at an average price of €24.00; as of market close on 18 September 2026, it held 1,527,534 ordinary shares. | 2026-09-23 | 2026-09-22 | |
| 6-K | — | 2026-09-15 | — | |
| Investor Event Transcript | — | 2026-09-15 | 2026-09-30 | |
| 6-K | — | 2026-09-08 | — | |
| 6-K | — | 2026-09-08 | — | |
| 6-K | — | 2026-09-01 | — | |
| 6-K | — | 2026-08-25 | — | |
| 6-K | — | 2026-08-25 | — | |
| 6-K | — | 2026-08-25 | — | |
| 6-K | — | 2026-08-18 | — | |
| 6-K | — | 2026-08-12 | — | |
| 6-K | — | 2026-08-12 | — | |
| 6-K | — | 2026-08-04 | — | |
| 6-K | — | 2026-07-28 | — | |
| 6-K | — | 2026-07-21 | — | |
| 6-K | — | 2026-07-15 | 2026-07-14 | |
| 6-K | — | 2026-07-13 | — | |
| 6-K | — | 2026-07-07 | — | |
| 6-K | — | 2026-06-30 | — | |
| 6-K | — | 2026-06-30 | 2026-06-29 | |
| 6-K | — | 2026-06-24 | 2026-06-23 | |
| 6-K | — | 2026-06-16 | — | |
| 6-K | — | 2026-06-09 | 2026-06-08 | |
| 6-K | — | 2026-06-09 | — | |
| 6-K | — | 2026-06-05 | 2026-06-04 | |
| 6-K | — | 2026-05-27 | 2026-05-26 | |
| 6-K | — | 2026-05-06 | — | |
| 6-K | — | 2026-04-29 | 2026-04-28 | |
| Investor Event Transcript | — | 2026-03-31 | — | |
| 6-K | — | 2026-03-31 | — | |
| 6-K | — | 2026-03-30 | — | |
| 20-F | — | 2026-03-26 | 2025-12-31 | |
| 6-K | — | 2026-03-24 | 2026-03-23 | |
| 6-K | — | 2026-03-17 | — | |
| 6-K | — | 2026-03-10 | — | |
| 6-K | — | 2026-03-06 | — | |
| 6-K | — | 2026-03-05 | — | |
| 6-K | — | 2026-03-04 | — | |
| 6-K | — | 2026-02-23 | — | |
| 6-K | — | 2026-02-19 | — | |
| 6-K | — | 2026-02-17 | 2026-02-16 | |
| 6-K | — | 2026-02-10 | — | |
| 6-K | — | 2026-01-05 | — | |
| 6-K | — | 2025-12-18 | — |
Showing 1–50 of 254 filings
Key facts
CIK
1421876
CUSIP
36315X101
13F (30d)
14 filings
14 filers
Visit website
Investor relations